On a Stepwise Quantitative Approach for Benefit-Risk Assessment

被引:2
|
作者
He, Weili [1 ]
Sun, Yaxuan [2 ]
Li, Qing [1 ]
Wan, Sabrina [1 ]
机构
[1] Merck & Co Inc, Clin Biostat, Kenilworth, NJ USA
[2] Iowa State Univ, Dept Stat, Ames, IA USA
关键词
benefit-risk assessment; standardized scores; probability of technical success; framework; joint evaluation; benefit-risk trade-offs;
D O I
10.1177/2168479017696274
中图分类号
R-058 [];
学科分类号
摘要
The field of structured benefit-risk assessment has evolved rapidly in the last few years with a great deal of regulatory and industry-wide initiatives. The available structured approaches to benefit-risk assessments exhibit and share many common elements in terms of defining the decision problem and therapeutic context, identifying key benefit and risk factors, and interpreting and communicating benefit-risk findings. However, there is limited guidance with these initiatives that is specific to metrics and methods to conduct benefit-risk assessment. Although we agree that benefit-risk metrics and analysis methods may be specific to individual clinical settings, we believe that there are general principles that can be followed. In this article, we propose a stepwise quantitative approach for benefit-risk assessment. We applied the stepwise quantitative approach to 3 real case studies.
引用
收藏
页码:625 / 634
页数:10
相关论文
共 50 条
  • [1] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    Weili He
    Yaxuan Sun
    Qing Li
    Sabrina Wan
    [J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
  • [2] A Quantitative Approach to Benefit-Risk Assessment: An Example with Lumiracoxib
    Primatesta, Paola
    Plana, Estel
    Moore, Alan
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S139 - S139
  • [3] A Bayesian Approach for Benefit-Risk Assessment
    Zhao, Yueqin
    Zalkikar, Jyoti
    Tiwari, Ram C.
    LaVange, Lisa M.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04): : 326 - 337
  • [4] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [5] Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature
    Kurzinger, Marie-Laure
    Douarin, Ludivine
    Uzun, Ievgeniia
    El-Haddad, Chantal
    Hurst, William
    Juhaeri, Juhaeri
    Tcherny-Lessenot, Stephanie
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
  • [6] Quantitative benefit-risk assessment: Hands-on workshop
    Ataher, Quazi S.
    Postmus, Douwe
    Hillege, Hans L.
    Tervonen, Tommi
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 360 - 360
  • [7] Semi-Quantitative Benefit-Risk Assessment for Dengvaxia
    Marcelon, Lydie F.
    Cohen, Carine H.
    Khromava, Alena
    Ochiai, Leon R.
    Wartel, Anh T.
    Gailhardou, Sophia
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 289 - 290
  • [8] Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
    Caster, Ola
    Edwards, I. Ralph
    [J]. BMC NEUROLOGY, 2015, 15
  • [9] A Comprehensive Approach to Benefit-Risk Assessment in Drug Development
    Sarac, Sinan B.
    Rasmussen, Christian H.
    Rasmussen, Morten A.
    Hallgreen, Christine E.
    Soeborg, Tue
    Colding-Jorgensen, Morten
    Christensen, Per K.
    Thirstrup, Steffen
    Mosekilde, Erik
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 (01) : 65 - 72
  • [10] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
    Warner, Margaret R.
    Wolka, Anne M.
    Noel, Rebecca A.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (03) : 342 - 346